Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Reuters

Published November 12, 2026 · Updated November 13, 2026

US to fund new research into psychedelic drug ibogaine for veterans with PTSD | Reuters

Read the full story at Reuters

The US government will spend up to $4.9 million to prepare for clinical trials of psychedelic drug ibogaine as a possible treatment for veterans.

Surfaced by 3 Google Alerts

  • Ibogaine
  • Ketamine
  • Psychedelics